This result suggests an association between elevated CSF 14-3-3β levels and the presence of both amyloid-beta and tau pathologies, which are indicative of an advanced pathological stage of Alzheimer’s disease.30 Consequently, results of this study imply that CSF levels of 14-3-3β may serve as a potential biomarker for the presence and severity of the core pathologies of Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.